Natera Files Suit Against ArcherDX for Patent Infringement

National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera MRD Testing in Stage II-III Colorectal Cancer

Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx

Natera Statement Regarding CareDx Suit

Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera Patients with Stage II-III Colorectal Cancer

Natera to Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference

Natera Announces Achievement of $55 Million in Pharma Contracts and Issuance of New Oncology Patents

Natera Receives Final Medicare Coverage for Prospera™ Organ Transplant Rejection Test

Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies 

Natera Reports Third Quarter 2019 Financial Results

Natera Announces Third Quarter 2019 Earnings Conference Call

Natera Announces Pricing of Follow-On Offering

Natera Launches Proposed Follow-On Offering

Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

CBR to Acquire Natera's Evercord™ Cord Blood Business

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

Natera to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

Natera Appoints Rowan Chapman to its Board of Directors

Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference

Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer

Panorama NIPT Achieves 2 Milion Test Milestone

Natera Reports Second Quarter 2019 Financial Results

Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies

Natera Announces Second Quarter 2019 Earnings Conference Call

New ProActive™ Study From Natera Will Test for Rejection in 3,000 Kidney Transplant Recipients

Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers

Natera Reports First Quarter 2019 Financial Results

New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier

Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards

FDA Grants Breakthrough Device Designation to Natera's Signatera Test

Natera Announces First Quarter 2019 Earnings Conference Call

New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test

Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

Natera Reports Fourth Quarter and Fiscal Year 2018 Financial Results

Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform

Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call

Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay

Natera Presents Outcomes Data at SMFM Annual Meeting Showing Strong Clinical Performance of Its SNP-Based Non-Invasive Prenatal Test

Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test

Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection

Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference

Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology

Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman 

Natera Presents Breast Cancer Data at SABCS Showing Ability of  Signatera  (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response

Natera Achieves Enrollment Goal of 20,000 Patients in SMART Study

Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test

Natera Reports Third Quarter 2018 Financial Results

Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine

Natera Announces Pricing of Follow-On Offering

Natera Develops Powerful Kidney Transplant Rejection Biomarker

Natera and Institut Jules Bordet Announce Collaboration in Neoadjuvant Breast Cancer

Natera Announces New Clinical Utility Data and Issuance of CPT Code for NIPT in Twin Pregnancies